Financials data is unavailable for this security.
View more
Year on year Fusion Antibodies PLC 's revenues fell -39.55%from 4.80m to 2.90m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 116.33% reduction in net income from a loss of 1.20m to a larger loss of 2.60m.
Gross margin | -7.41% |
---|---|
Net profit margin | -179.67% |
Operating margin | -191.32% |
Return on assets | -93.94% |
---|---|
Return on equity | -140.93% |
Return on investment | -130.56% |
More ▼
Cash flow in GBPView more
In 2023, cash reserves at Fusion Antibodies PLC fell by 1.85m. Cash Flow from Financing totalled 3.00k or 0.10% of revenues. In addition the company used 1.75m for operations while cash used for investing totalled 111.00k.
Cash flow per share | -0.0712 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0245 |
---|---|
Tangible book value per share | 0.0245 |
More ▼
Balance sheet in GBPView more
Current ratio | 3.26 |
---|---|
Quick ratio | 2.32 |
Total debt/total equity | 0.0323 |
---|---|
Total debt/total capital | 0.0313 |
More ▼